Yahoo Finance

Octapharma Releases Results for Phase 3 Superiority Study of Pediatric Acute-onset Neuropsychiatric Syndrome

PARAMUS, N.J., May 28, 2025 /PRNewswire/ -- Octapharma has released the results from its prospective, randomized, double-blind, parallel group, crossover, placebo-controlled phase 3 study comparing ...
Finanznachrichten

Octapharma: Patient recruitment starts for the international PRO-SID study evaluating Panzyga for primary prophylaxis in patients with chronic lymphocytic leukaemia and ...

Octapharma is pleased to announce that the first site for the international PRO-SID (Primary Infection Prophylaxis with Panzyga in Secondary Immunodeficiency in Chronic Lymphocytic Leukaemia) study ...
Yahoo Finance

Pfizer's PANZYGA Wins FDA Approval For Rare Peripheral Nerves Disorder

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Financial Post

Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary ...

LACHEN, Switzerland — Octapharma is pleased to announce that the first site for the international PRO-SID (Primary Infection Prophylaxis with Panzyga ® in Secondary Immunodeficiency in Chronic ...